Plasma Nevirapine Levels and 24‐Week Efficacy in HIV‐Infected Patients Receiving Nevirapine‐Based Highly Active Antiretroviral Therapy with or without Rifampicin | Zendy

Weerawat Manosuthi | Zendy; Somnuek Sungkanuparph | Zendy; Ammarin Thakkinstian | Zendy; Sasivimol Rattanasiri | Zendy; Achara Chaovavanich | Zendy; Wisit Prasithsirikul | Zendy; Sirirat Likasakul | Zendy; Kiat Ruxrungtham | Zendy

Open Access

Plasma Nevirapine Levels and 24‐Week Efficacy in HIV‐Infected Patients Receiving Nevirapine‐Based Highly Active Antiretroviral Therapy with or without Rifampicin

Author(s) -

Weerawat Manosuthi,

Somnuek Sungkanuparph,

Ammarin Thakkinstian,

Sasivimol Rattanasiri,

Achara Chaovavanich,

Wisit Prasithsirikul,

Sirirat Likasakul,

Kiat Ruxrungtham

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/505210

Subject(s) - nevirapine , medicine , rifampicin , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , sida , viral disease , viral load , tuberculosis , pathology

Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P=.048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P>.05).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research